Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Amgen scores with trial of on-body injected version of Tepezza in thyroid eye disease
Amgen has found a potential way to boost sales of its thyroid eye disease (TED) treatment, Tepezza, through a new patient-friendly subcutaneous injection administered via an on-body injector (OBI). A phase 3 trial demonstrated that Tepezza OBI achieved comparable efficacy to the current intravenous (IV) formulation, meeting its primary endpoint with a 77% proptosis response rate. This new delivery method aims to increase patient convenience and accessibility for the drug, which has seen stagnant sales despite being the only approved treatment for TED.